Camille Samuels is a Partner at Venrock, a venture capital firm originally founded by the Rockefeller family in the 1960s. She focuses on healthcare investing, particularly in biotech, medical devices, and consumer medicine. Camille currently serves on the board of Spirox and Unity, having recently stepped off the board of RegenXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade where she led investments in Kythera (KYTH -- acquired by
Allergan), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among others, and was a board observer at several companies including Genomic Health (GHDX), Fluidigm (FLDM), and Syrrx (acquired by Takeda).
Before Versant, she was responsible for business development at Tularik and worked in corporate development and strategic marketing at Genzyme and Millennium Predictive Medicine. She also worked at LEK Consulting.
Cami studied Biology at Duke and received an MBA from Harvard, where she graduated as a Baker Scholar.